+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2013



Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2013



Current Medical Research and Opinion 33(3): 473-478



The objective of this study was to assess the timely disclosure of results of company-sponsored clinical trials related to all new medicines approved by the European Medicines Agency (EMA) during 2013. This is an extension of two previously reported studies of trials related to all new medicines approved in Europe in 2009, 2010 and 2011, and in 2012. The original study found that over a three year period over three-quarters of all trials were disclosed within 12 months and almost 90% were disclosed by the end of the study. The extension study (2012 approvals) showed an improvement in results disclosure within 12 months to 90%, and an overall disclosure rate of 92% by the end of the study. The methodology used was exactly as previously reported. Various publicly available information sources were searched for both clinical trial registration and disclosure of results. All completed company-sponsored trials related to each new medicine approved for marketing by the EMA in 2013, carried out in patients and recorded on a clinical trials registry and/or included in an EMA European Public Assessment Report (EPAR), were included. Information sources were searched between 1 May and 31 July 2015. The main outcome measure was the proportion of trials for which results had been disclosed on a registry or in the scientific literature either within 12 months of the later of either first regulatory approval or trial completion, or by 31 July 2015 (end of survey). Of the completed trials associated with 34 new medicines licensed to 24 different companies in 2013, results of 90% (484/539) had been disclosed within 12 months, and results of 93% (500/539) had been disclosed by 31 July 2015. The disclosure rate within 12 months of 90% suggests that industry is continuing to achieve disclosure in a timely manner. The overall disclosure rate at study end of 93% indicates that the improvement in transparency amongst company-sponsored trials has been maintained in the trials associated with new medicines approved in 2013.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057426729

Download citation: RISBibTeXText

PMID: 27869482

DOI: 10.1080/03007995.2016.1263612


Related references

Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2012. Current Medical Research and Opinion 31(7): 1431-1435, 2015

Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2014. Current Medical Research and Opinion 34(7): 1239-1243, 2018

Clinical trial transparency: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved recently in Europe. Current Medical Research and Opinion 30(3): 395-405, 2014

Withholding unfavourable results in drug company sponsored clinical trials. Lancet 1(8541): 1091, 1987

Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency. Revista Panamericana de Salud Publica 30(1): 87-96, 2011

Scarce quality assurance documentation in major clinical trial registries for approved medicines used in post-marketing clinical trials. Trials 20(1): 212, 2019

Guidelines for company-sponsored Safety Assessment of Marketed Medicines (SAMM) guidelines. Medicines Control Agency, Committee on Safety of Medicines, Royal College of General Practitioners, British Medical Association and Association of the British Pharmaceutical Industry (November 1993). British Journal of Clinical Pharmacology 38(2): 95-97, 1994

Clinical trial registration: a step forward in providing transparency for the positive and negative results of clinical trials. Archives of Dermatology 141(1): 75, 2005

Review of multicentre clinical trials is simplified; more trial centres are approved in the first assessment round. Nederlands Tijdschrift Voor Geneeskunde 158: A7558-A7558, 2014

Clinical trials transparency and the Trial and Experimental Studies Transparency (TEST) act. Contemporary Clinical Trials 37(2): 219-224, 2014

Clinical safety data management in company non-sponsored trials. Nihon Rinsho. Japanese Journal of Clinical Medicine 61(9): 1658-1665, 2003

More transparency for clinical trial data: The decision by the European Medicines Agency to make clinical trial reports publicly available could provide a boon for biomedical research. Embo Reports 16(1): 21-23, 2015

Guidelines for monitoring company sponsored clinical trials in the pharmaceutical industry. Controlled Clinical Trials 12(5): 715-716, 1991

Researchers raise concerns about secrecy in company-sponsored clinical trials. Chronicle of Higher Education 52(31): A29, 2006

Trials, tricks and transparency: how disclosure rules affect clinical knowledge. Journal of Health Economics 28(6): 1141-1153, 2009